Melanotan I vs Melanotan II: Mechanism, Melanoma Risk, and How Afamelanotide Differs

Melanotan I and Melanotan II are both synthetic analogs of alpha-melanocyte-stimulating hormone (α-MSH), but they differ in one decisive way: receptor selectivity. Melanotan I is a selective melanocortin-1 receptor (MC1R) agonist approved in the EU and US as afamelanotide (Scenesse) for a rare light-sensitivity disorder, while Melanotan II is a non-selective melanocortin agonist that activates MC1R, MC3R, MC4R, and MC5R, has no regulatory approval anywhere, and is known mainly through adverse-event case reports. That single difference — one receptor versus four — explains nearly every downstream contrast in how the two peptides feel, what they do, and how risky they are.

Most people comparing these two compounds are not researchers — they are trying to pick one for a reason. The reasons are well documented: a cosmetic tan without UV exposure (by far the most common motivation), a libido or erectile effect, and appetite suppression. Both compounds belong to the skin, anti-aging, and cosmetic peptide category and both are sold grey-market as "tanning peptides," so it is easy to assume the choice is simply "which one tans better." It is not. As this guide shows, the two peptides are not interchangeable, the safer-looking option is not realistically available for cosmetic use, and the comparison that matters most is the documented risk profile.

What is the difference between Melanotan I and Melanotan II?

Melanotan I is a linear 13-amino-acid α-MSH analog (molecular weight 1646.85 Da) that selectively activates MC1R and is approved as the prescription drug afamelanotide (Scenesse). Melanotan II is a smaller cyclic 7-amino-acid heptapeptide (molecular weight 1024.18 Da) that activates four melanocortin receptors (MC1R, MC3R, MC4R, MC5R), has no approval in any country, and produces systemic effects far beyond tanning. The two differ in structure, receptor targeting, and legal status, all of which trace back to selectivity: Melanotan I was engineered to preserve α-MSH's natural specificity, while Melanotan II was engineered for potency, trading selectivity away in the process.

The pattern is consistent: the selective peptide stayed in its lane and became an approved drug, while the non-selective peptide spread its activity across the body and stalled in development over safety concerns.

Which one fits which goal?

For a beginner, the honest decision framing is not "MT-1 versus MT-2" — it depends on the goal, and in most cases the choice is narrower than it appears. For a cosmetic tan, the two are not realistically interchangeable: Melanotan I exists only as the supervised prescription implant afamelanotide and is not legally or practically available for cosmetic tanning, so the real-world grey-market choice is Melanotan II versus not using a peptide at all. That reframes the question — it is not "which tanning peptide is better" but "is the documented risk of Melanotan II acceptable for a cosmetic goal," which is a different and more sober question.

A common belief drives the cosmetic choice: that an injected tan is safer than a sunbed because it avoids UV. Mechanistically this is backwards for Melanotan II. A UV tan stimulates melanocytes in the skin; Melanotan II stimulates melanocytes throughout the body, indiscriminately, which is precisely the basis for its melanoma concern. "No UV" does not mean "no melanocyte risk."

How does each peptide work?

Both peptides work by mimicking α-MSH at melanocortin receptors, triggering a cyclic adenosine monophosphate (cAMP) signaling cascade that activates the enzyme tyrosinase and drives melanin production — specifically the darker, UV-absorbing form called eumelanin rather than the red-yellow pheomelanin. The difference is reach. Melanotan I's structure preserves α-MSH's selectivity for MC1R, which melanocytes express at roughly 100 to 1,000 times the density of other tissues, so its action stays skin-confined. Melanotan II's cyclic structure trades that selectivity for potency, activating four melanocortin receptor subtypes and producing effects throughout the body.

Melanotan I (MT-1) is a synthetic 13-amino-acid analog of α-MSH carrying two structural substitutions — norleucine at position 4 and D-phenylalanine at position 7 — that resist enzymatic breakdown and extend its half-life while preserving the His-Phe-Arg-Trp core sequence that confers MC1R selectivity. It was developed at the University of Arizona in the 1980s and 1990s by the research groups of Mac Hadley and Robert Dorr; their team's 2004 human study, "Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers" in Archives of Dermatology, demonstrated UV-assisted tanning across three Phase 1 trials. The regulated form is catalogued as afamelanotide on DrugBank. Preclinical and in vitro work demonstrates that MC1R activation does more than darken skin: it upregulates nucleotide excision repair, a DNA-repair pathway that corrects UV-induced mutations. Melanotan II (MT-2), by contrast, is a shorter cyclic heptapeptide closed by a lactam bridge between aspartic acid (position 2) and lysine (position 7); the cyclization boosts potency and stability but eliminates the selectivity, so MT-2 binds MC1R, MC3R, MC4R, and MC5R with meaningful affinity. For a deeper treatment of MT-2's pigmentation and libido pathways, see Peptigrity's Melanotan II mechanism breakdown.

What is the role of afamelanotide here?

Afamelanotide is the regulated form of Melanotan I, marketed as Scenesse and delivered as a subcutaneous implant rather than an injection. It is approved by both the FDA and the European Medicines Agency to reduce phototoxicity in erythropoietic protoporphyria (EPP), a rare inherited disorder — estimated to affect roughly 1 in 75,000 to 1 in 200,000 people — in which sunlight causes severe pain. Clinuvel pursued afamelanotide as photoprotection precisely because MC1R selectivity makes it behave like an internal sunscreen with built-in DNA-repair support, not a cosmetic tanning shortcut. Its approval validates the melanocortin-tanning concept while underscoring why the non-selective version never made it through development.

Why do their effects differ so much?

The effects differ because each melanocortin receptor governs a different physiological system, and Melanotan II activates all four while Melanotan I activates only one. MC1R drives skin pigmentation, which is why both peptides tan. But Melanotan II also engages MC3R and MC5R — receptors involved in energy balance, sebaceous gland activity, and lipid metabolism — and, most consequentially, MC4R, which controls appetite and sexual arousal. MC4R activation is why Melanotan II users report nausea, appetite suppression, and spontaneous erections, effects that Melanotan I largely avoids through its MC1R selectivity. The same MC4R mechanism is the foundation for a separate, FDA-approved drug.

The early human observation that Melanotan II triggered erections — documented in melanocortin research led by Mac Hadley and Robert Dorr, summarized in their Peptides review "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization" — is what spawned an entire drug-development program around MC4R and sexual function.

How does Melanotan II relate to PT-141 (bremelanotide)?

PT-141 (bremelanotide) is the MC4R-targeted descendant of Melanotan II, developed specifically to isolate the sexual-arousal effect and discard the tanning and broad-receptor activity. Unlike Melanotan II, it achieved regulatory approval: the FDA approved bremelanotide (brand name Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women. In other words, Melanotan II's "side effect" became another molecule's primary indication. Readers comparing the two should not confuse them — PT-141 is not a tanning agent. For the receptor science behind it, see Peptigrity's PT-141 bremelanotide mechanism guide.

Is Melanotan II more dangerous than Melanotan I?

Yes — on the available evidence, Melanotan II carries a substantially higher documented risk than Melanotan I. Because Melanotan II stimulates melanocytes indiscriminately, case reports link it to darkening moles, rapidly appearing dysplastic nevi, and at least four melanomas emerging during or after use. Other reports describe rhabdomyolysis with acute kidney injury, priapism, and renal infarction. Melanotan I, as the approved drug afamelanotide, carries regulatory-grade safety data within its narrow medical indication — but that record reflects supervised medical use of an implant, not unregulated vials self-injected for cosmetic tanning.

The core mechanistic problem is that melanocyte stimulation does not discriminate between normal skin and pre-existing melanocytic lesions. A 2017 review by Habbema and colleagues, "Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues" in the International Journal of Dermatology, compiled the cutaneous complications reported across the melanotan literature, including darkening of existing moles, the rapid appearance of new and dysplastic nevi, and changes in the size and shape of pre-existing lesions — clinically significant because dysplastic nevi are recognized melanoma precursors. The review noted four case reports describing melanomas emerging from existing moles during or shortly after melanotan use. A separate 2014 report, "Melanoma associated with the use of melanotan-II", documented melanoma in-situ in a Melanotan II user, and at least one such case involved product from a regulated compounding pharmacy — which means purity alone does not remove the carcinogenesis concern.

The systemic risks are equally striking. A widely cited 2012 case report by Nelson and colleagues, "Melanotan II injection resulting in systemic toxicity and rhabdomyolysis" in Clinical Toxicology, described a 39-year-old man who developed sympathomimetic toxicity, rhabdomyolysis (with creatine kinase peaking near 17,773 IU/L), and acute kidney injury after a single 6 mg subcutaneous injection of internet-purchased Melanotan II. A 2020 report by Peters and colleagues in CEN Case Reports documented a previously normotensive man who developed hypertension and a right-sided renal infarction after six months of subcutaneous Melanotan II. Priapism — a prolonged, painful erection requiring emergency intervention — has also been documented, including the 2019 BMJ Case Reports case "Melanotan-induced priapism: a hard-earned tan", reflecting the same MC4R activity that drives the libido effect.

These reports do not prove that Melanotan II causes melanoma — they establish an association, and case reports sit below controlled trials in the evidence hierarchy. But for a compound with little human RCT safety data, case reports are the highest-level signal available, and the mechanistic plausibility (indiscriminate melanocyte stimulation) makes them hard to dismiss. On this basis, Melanotan II is generally considered contraindicated for anyone with a personal or family history of melanoma or dysplastic nevi, cardiovascular disease, or during pregnancy and breastfeeding, and dermatological mole screening is advised for anyone who has used it. For a broader view of how risks differ across compounds and administration routes, see Peptigrity's peptide side effects by compound and route reference. None of this is medical advice — these decisions belong with a qualified clinician.

What is the legal and regulatory status of each?

Their legal status could hardly be more different. Melanotan I is approved by the FDA and EMA as afamelanotide (Scenesse), but only as a prescription implant for the rare disorder EPP — never as a cosmetic tan. Melanotan II has no regulatory approval anywhere and is sold only as a "research use only" chemical. As of May 2026, the US regulatory picture is shifting in a way that surprised much of the peptide community.

In late 2023, the FDA placed 19 peptides — including Melanotan II — into Category 2 of its interim 503A bulk drug substances list, the designation for compounds it considered to pose significant safety concerns, which prevented compounding pharmacies from preparing them. For years, observers expected Melanotan II to remain in Category 2 over its melanoma and cardiovascular signals. Instead, on April 15, 2026, the FDA announced the removal of Melanotan II (alongside 11 other peptides) from Category 2, effective April 22, 2026. Removal from Category 2 does not equal Category 1 status or 503A approval — it does not authorize compounding by itself. Each substance still requires individual Pharmacy Compounding Advisory Committee (PCAC) review followed by formal rulemaking before pharmacies can act. Reporting on the exact PCAC timing for Melanotan II is inconsistent, with some sources placing its review later than the July 2026 batch.

Because this landscape is actively moving, the current status should be verified before relying on it. Peptigrity tracks these developments in its FDA peptide regulation timeline and its country-by-country legal status guide. The short version: afamelanotide is a supervised prescription drug for a rare condition, not a legal cosmetic tanning product, and Melanotan II remains unapproved for human use regardless of its compounding-list reclassification.

How would you verify the quality of melanotan you bought?

If you are evaluating any melanotan product, verification is harder than for most peptides, because neither version is sold through a regulated cosmetic channel — and because at least one documented melanoma case involved product from a licensed compounding pharmacy, purity alone does not remove the risk. At minimum, confirm an HPLC purity result, a mass-spectrometry identity match to the correct molecular weight, and a certificate of analysis (CoA) from a named third-party laboratory. Quality verification is the part of this decision most buyers skip and the part Peptigrity exists to support.

Peptigrity operates as an independent platform that publishes third-party HPLC purity data and community reviews — currently tracking 235 shops and 6,512 independent lab tests across 64 peptides (verified May 2026), with trust scores weighted as lab purity (60%) plus reviews (40%) and no option for a shop to pay to change its score. You can compare independent lab test results across vendors, learn the verification fundamentals at the how to test peptides hub, and see exactly what a clean report looks like in the guide to reading peptide lab test results by HPLC and mass spec. For melanotan specifically, the verification question matters less than the prior question — whether the documented risk profile makes the purchase worth making at all.

Frequently Asked Questions

Which melanotan should I choose for tanning?

For a cosmetic tan, the two are not a real either-or choice. Melanotan I exists only as the supervised prescription implant afamelanotide (Scenesse), approved for the rare disorder EPP, so it is not legally or practically available for cosmetic use — which means the grey-market "choice" is effectively Melanotan II or nothing. The honest question is therefore not which tanning peptide is better, but whether Melanotan II's documented melanoma and systemic-toxicity signals are an acceptable trade for a tan. If the goal is a libido effect rather than a tan, the regulated route is PT-141 (bremelanotide), not Melanotan II.

Which melanotan tans faster?

Melanotan II typically darkens skin faster and at lower doses than Melanotan I because its cyclic structure makes it more potent across melanocortin receptors. Speed, however, is not the relevant safety variable — the faster, broader receptor activity is exactly what produces Melanotan II's systemic side effects and its melanocyte-stimulation risk. A faster tan from a less selective peptide is not a safer one.

Is afamelanotide the same as Melanotan I?

Yes. Afamelanotide is the regulated, clinically developed form of Melanotan I, marketed as Scenesse and FDA- and EMA-approved as a subcutaneous implant for erythropoietic protoporphyria (EPP). The names refer to the same selective MC1R agonist; "afamelanotide" is the approved-drug designation, while "Melanotan I" is the original research name still used in grey-market contexts.

Can Melanotan II cause skin cancer?

Case reports associate Melanotan II with melanoma and with the appearance of new and dysplastic (atypical) nevi, and the mechanistic concern is real, because MC1R activation stimulates melanocytes without distinguishing normal skin from pre-existing lesions. Causation has not been proven in controlled trials, but the combination of reported cases and biological plausibility is why dermatological screening is recommended for anyone who has used it.

What's the difference between Melanotan II and PT-141?

PT-141 (bremelanotide) is an MC4R-targeted descendant of Melanotan II, developed to isolate the sexual-arousal effect, and it is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Melanotan II is a non-selective tanning peptide with no approval. They share a melanocortin origin but are different molecules with different purposes.

Is Melanotan I legal to buy for tanning?

No. Melanotan I is approved only as the prescription implant afamelanotide (Scenesse) for the rare disorder EPP, under medical supervision. It is not approved or legally sold as a cosmetic tanning product, and grey-market "Melanotan I" sold for tanning sits in the same unregulated research-chemical space as Melanotan II.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.